Skip to content
EmergingResearch compoundLimited evidence

RGPU‑95

Experimental nootropic related to phenylpiracetam: studied only in animals, with no human data.

NootropicRacetamRacetamDopamineFocusDopamineGlutamateAcetylcholineNorepinephrineAnti-fatigue

Pharmacology

ClassRacetam · Dopamine · Focus
Primary targetDopamine transporter (DAT) inhibitor
Targets4 receptor targets
Half-lifeN/A
OnsetN/A
EvidenceLimited evidence
Affected systemsDopamineGlutamateAcetylcholineNorepinephrineAnti-fatigue

Contents

DETAILED OVERVIEW

What is RGPU-95?

RGPU-95 is an experimental compound, a chlorine-containing relative of phenylpiracetam, a drug that is available by prescription in Russia. It is not approved as a medicine anywhere and exists only as a research chemical. It is not specifically named on the anti-doping list, but because of its similar structure it may fall under the catch-all group of stimulants.

So far it has been studied only in animals: one study in rodents saw an effect that looked like easing anxiety and depression. It probably mildly blocks the reuptake of dopamine, a brain messenger, but its mechanism is largely unknown. There is no safety or efficacy data in humans; possible side effects can only be assumed from related drugs, such as restlessness and insomnia.

Mechanism

DAT inhibitor (phenylpiracetam analog)

Half-life

N/A (no human data)

Onset

N/A (no human data)

Legal status

Research chemical, unapproved

Receptor profile

  • Dopamine transporter (DAT)Moderate
  • NMDA / AMPA glutamate receptorsModerate
  • Limbic anxiety-depression circuitsModerate
  • Nicotinic cholinergic toneWeak

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • No human safety data; the side-effect profile is inferred from the phenylpiracetam class and unverified in people
  • Possible overstimulation, restlessness or anxiety from dopaminergic/noradrenergic activity (by analogy to phenylpiracetam)
  • Possible insomnia or sleep disruption if dosed later in the day (stimulant-class analogy)
  • Possible headache from the cholinergic demand typical of racetams (a choline source may help)
  • Possible raised heart rate or blood pressure from dopaminergic stimulation (theoretical)
  • Unknown long-term and toxicity profile in humans; the purity of grey-market material is a separate risk

Contraindications · 6

  • Pregnancy and breastfeeding: no safety data, should be avoided
  • Cardiovascular disease, arrhythmia, hypertension: caution by analogy to dopaminergic stimulants
  • MAO inhibitors: avoid, risk of hypertensive crisis with dopaminergic agents
  • Other stimulants (caffeine, amphetamines): additive cardiovascular load
  • Anxiety disorders and insomnia: dopaminergic stimulation may worsen symptoms
  • Competitive athletes: as a phenylpiracetam analog it may fall under the WADA S6 catch-all (similar structure/effect)

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

RGPU-95 is a Russian relative of the better-known compound phenylpiracetam, studied specifically in animal experiments for anxiety-easing and mood-lifting effects. Rodent studies showed anxiolytic and antidepressant-like effects, and because it acts on the dopamine system it could theoretically support focus and motivation too, in line with the phenylpiracetam family. It's important to stress that this is a purely experimental compound with animal data only, no human trials or experience back it up.

Telegram

Have a question about RGPU‑95?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC12H13ClN2O2
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.